Hub : Traits :

Asthma (self-reported)

710 significantly associated models · 166 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 7715776 11137778 5 2 3.1e-09 4.1e-09 9.8e-02 92 KIF1B RERE
2 1 151055670 152712747 3 6 4.6e-12 1.8e-13 1.0e+00 100 LINGO4 S100A11 TDRKH
3 1 166702558 168182443 1 1 3.0e-12 2.0e-12 1.0e+00 100 CD247
4 1 172311679 173713130 2 1 3.6e-08 4.4e-08 3.6e-09 -16 TNFSF4
5 1 202888496 203393566 1 1 5.9e-09 1.1e-08 1.0e+00 100 MYBPH
6 2 99922967 100994580 1 1 1.9e-07 4.8e-08 3.9e-02 86 AFF3
7 2 101994731 104027106 6 8 9.8e-63 9.1e-51 NaN NaN IL18R1 IL1R1 IL1RL1 SLC9A2
8 2 241941773 243048760 8 3 1.4e-24 4.6e-25 2.9e-01 99 D2HGDH ING5
9 3 127097277 128533990 2 1 9.6e-09 6.9e-08 3.8e-01 97 EEFSEC
10 4 38097478 39643536 4 1 4.1e-14 3.6e-15 4.0e-03 87 TLR1
11 4 122377715 123976639 1 1 3.6e-17 4.3e-14 7.6e-03 88 KIAA1109
12 5 35608310 36124514 1 1 6.1e-08 3.9e-08 1.0e+00 100 IL7R
13 5 109381583 111527482 5 7 4.0e-21 8.1e-40 NaN NaN SLC25A46 TMEM232 TSLP
14 5 130588008 132900729 16 7 3.8e-23 2.7e-25 NaN NaN AC034220.3 KIF3A P4HA2-AS1 SLC22A5
15 5 140789933 142230251 1 1 1.1e-09 2.9e-09 1.6e-02 84 NDFIP1
16 5 156131251 157697754 1 1 1.2e-09 1.3e-09 9.4e-04 70 ADAM19
17 6 25266147 26682323 1 1 1.6e-07 8.0e-10 1.0e-06 37 TRIM38
18 6 34528785 35987507 3 1 2.1e-08 1.1e-09 7.4e-03 81 ZNF76
19 6 63986735 64534000 1 1 3.5e-08 1.7e-08 8.5e-02 91 PTP4A1
20 6 89941356 91704536 1 2 7.0e-18 3.7e-27 3.7e-07 78 BACH2
21 6 134905567 136516257 2 2 2.0e-13 2.5e-09 7.1e-01 100 AHI1
22 7 27623776 28468319 1 1 5.8e-08 1.2e-13 3.4e-07 53 JAZF1
23 9 4934896 7345375 5 3 5.5e-28 1.5e-56 1.4e-22 62 GLDC KIAA1432 RANBP6
24 10 74879374 76266883 1 1 1.4e-07 4.0e-05 2.9e-01 93 RP11-574K11.5
25 10 93657148 95110026 1 1 1.3e-07 1.7e-08 9.8e-03 79 KIF11
26 11 60839578 62346131 6 1 3.8e-11 3.3e-11 3.9e-02 90 FADS1
27 11 64845438 66333072 4 1 3.6e-09 2.5e-10 1.7e-05 54 EFEMP2
28 11 75678647 77069746 1 1 2.6e-25 2.4e-44 7.9e-22 53 LRRC32
29 11 110776537 112287801 1 1 7.6e-09 1.1e-09 1.0e+00 100 SIK2
30 12 5809999 6956462 1 1 2.0e-07 1.6e-07 1.1e-01 91 RP1-102E24.8
31 12 47407397 48825686 1 1 6.5e-08 6.5e-06 1.5e-02 71 RP1-197B17.3
32 12 55601472 58677299 12 4 6.1e-17 1.6e-23 1.4e-02 94 GPR182 KIF5A RPS26 STAT6
33 12 120502726 122037099 1 1 1.3e-08 6.7e-08 5.1e-02 87 SPPL3
34 13 99047988 100728229 3 3 2.7e-13 6.1e-17 3.9e-02 94 UBAC2
35 14 92733536 93401178 1 1 1.9e-09 1.0e-05 8.4e-03 64 RIN3
36 15 66662107 68789191 4 4 5.2e-32 8.5e-37 6.5e-04 93 IQCH SMAD3
37 16 10325245 12010444 5 2 4.9e-19 2.3e-26 8.8e-07 79 CLEC16A RP11-396B14.2
38 16 26518263 28065536 5 2 3.3e-13 2.0e-12 9.0e-04 78 CTD-3203P2.1 IL4R
39 17 36710513 39068227 24 9 7.6e-52 1.4e-50 1.0e+00 100 CASC3 GSDMA KRT222 MED24 ORMDL3
40 17 39993748 41538783 4 1 6.4e-08 1.1e-07 4.4e-05 41 RP11-400F19.8
41 17 42624404 43570226 1 1 3.4e-09 3.6e-09 8.8e-03 80 CTD-2020K17.3
42 17 46581184 48139500 2 1 2.4e-14 5.9e-16 3.0e-03 86 ZNF652
43 18 51553172 52058680 1 1 1.4e-07 3.1e-06 4.1e-01 97 POLI
44 19 15771809 17268784 1 1 1.3e-07 7.8e-06 3.6e-03 58 EPS15L1
45 19 45585167 46994833 3 1 7.6e-09 1.0e-09 4.0e-02 89 DMWD
46 19 52049899 52574723 1 1 3.0e-07 1.5e-05 3.1e-04 31 FPR3
47 20 62024275 62614338 2 1 4.5e-08 2.9e-06 8.5e-01 100 STMN3
48 22 41071659 42685537 7 1 3.1e-08 8.0e-08 4.9e-01 98 PHF5A

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.36 1 0 0.0 0.00 1.0e+00 MED24
Bipolar Disorder or Schizophrenia 1.41 3 0 0.0 0.00 1.0e+00 MED24 STAT6 TRIM38
Depressed Affect (Nagel 2018) 1.04 2 0 0.0 0.00 1.0e+00 PHF5A RERE
Intelligence (Savage-Jansen 2018) 0.82 2 1 2.2 0.00 1.0e+00 AFF3 RPS26
Neuroticism (Nagel 2018) 1.07 1 0 0.0 0.00 1.0e+00 PHF5A
Schizophrenia (2018) 1.20 2 1 2.2 0.00 1.0e+00 STAT6 TRIM38
Worry (Nagel 2018) 0.92 1 0 0.0 0.00 1.0e+00 TRIM38
Crohns Disease (2017) 5.72 18 9 20.0 -0.13 5.7e-01 AC034220.3 BACH2 CASC3 FADS1 GSDMA KIAA1109 KIF11 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RP11-574K11.5 SLC22A5 SMAD3 STMN3 TNFSF4
Irritable Bowel Disease (IBD) 5.37 17 13 28.9 -0.12 5.8e-01 AC034220.3 BACH2 CASC3 GSDMA KIAA1109 KIF11 KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 RP11-574K11.5 SLC22A5 SMAD3 STMN3
Ulcerative Colitis (UC) 3.15 9 5 11.1 -0.09 7.8e-01 CASC3 GSDMA KIAA1109 KRT222 LINGO4 LRRC32 MED24 ORMDL3 SMAD3
Reaction Time 1.06 1 0 0.0 0.00 1.0e+00 MED24
Verbal and Numeric Reasoning (VNR) 0.99 2 0 0.0 0.00 1.0e+00 AFF3 RPS26
Breast Cancer 1.82 7 3 6.7 0.65 7.9e-02 EFEMP2 KIF1B P4HA2-AS1 RP11-400F19.8 SIK2 SLC22A5 TLR1
Prostate Cancer 1.79 2 1 2.2 0.00 1.0e+00 EEFSEC STMN3
Body Mass Index (BMI) (2010) 1.12 1 0 0.0 0.00 1.0e+00 SMAD3
Crohns Disease (2012) 4.58 10 6 13.3 -0.24 4.3e-01 AC034220.3 FADS1 GSDMA LRRC32 NDFIP1 ORMDL3 P4HA2-AS1 SLC22A5 SMAD3 STMN3
Fasting Glucose 1.30 1 1 2.2 0.00 1.0e+00 FADS1
HDL Cholesterol 2.21 5 2 4.4 -0.17 7.8e-01 FADS1 FPR3 GSDMA KIF5A ORMDL3
LDL Cholesterol 1.38 1 1 2.2 0.00 1.0e+00 FADS1
Lupus 1.63 1 0 0.0 0.00 1.0e+00 ZNF76
Primary Biliary Cirrhosis 2.25 3 2 4.4 0.00 1.0e+00 GSDMA IL7R ORMDL3
Rheumatoid Arthritis 1.72 1 0 0.0 0.00 1.0e+00 ORMDL3
Schizophrenia (2014) 1.03 1 0 0.0 0.00 1.0e+00 STAT6
Triglycerides 1.78 2 2 4.4 0.00 1.0e+00 FADS1 KIF5A
Type 2 Diabetes (T2D) (2012) 1.62 2 1 2.2 0.00 1.0e+00 JAZF1 KIF11
Ulcerative Colitis 2.65 4 2 4.4 -0.64 3.6e-01 GSDMA KIAA1109 MED24 ORMDL3
Blood Eosinophil Count 27.60 52 46 102.2 0.91 5.6e-28 AC034220.3 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-3203P2.1 D2HGDH DMWD EFEMP2 FADS1 FPR3 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KRT222 LRRC32 MED24 NDFIP1 P4HA2-AS1 PHF5A POLI RANBP6 RERE RIN3 RP1-102E24.8 RP11-396B14.2 RPS26 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 TMEM232 TSLP UBAC2 ZNF652 ZNF76
Blood Platelet Count 2.23 19 18 40.0 0.41 6.2e-02 AC034220.3 DMWD EEFSEC FADS1 ING5 KIF1B KIF3A KIF5A MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RP1-102E24.8 RP1-197B17.3 SIK2 SLC22A5 SPPL3 STMN3
Blood Red Count 1.02 12 6 13.3 0.13 6.6e-01 AFF3 AHI1 BACH2 FADS1 KIF11 KIF5A LINGO4 NDFIP1 POLI RPS26 SPPL3 TLR1
Blood White Count 13.18 27 18 40.0 0.62 4.6e-05 AC034220.3 AHI1 BACH2 CASC3 CLEC16A EFEMP2 EPS15L1 FADS1 GSDMA IL1RL1 KIF1B KIF3A MED24 NDFIP1 ORMDL3 P4HA2-AS1 POLI RERE RIN3 RP1-102E24.8 RP11-396B14.2 RP11-400F19.8 SLC22A5 SPPL3 STMN3 ZNF652 ZNF76
Heel T-Score 0.90 10 6 13.3 -0.16 6.6e-01 BACH2 FADS1 FPR3 IQCH KIF1B PHF5A RERE RIN3 RPS26 ZNF76
BMI 0.92 8 4 8.9 0.28 4.9e-01 EEFSEC IQCH PTP4A1 RP11-400F19.8 RPS26 SMAD3 STMN3 TLR1
Height 1.82 21 13 28.9 -0.56 4.8e-03 AC034220.3 AFF3 AHI1 CASC3 DMWD FADS1 IL1R1 IL1RL1 IQCH KIF11 KIF1B NDFIP1 P4HA2-AS1 PHF5A RERE SLC22A5 SMAD3 SPPL3 STAT6 ZNF652 ZNF76
Waist Hip Ratio (WHR) 1.18 7 0 0.0 0.02 9.6e-01 AFF3 DMWD IQCH MED24 RP11-396B14.2 RP11-400F19.8 SIK2
Systolic Blood Pressure 1.02 8 4 8.9 0.41 3.1e-01 CTD-2020K17.3 DMWD EEFSEC KIF11 RERE SIK2 SMAD3 ZNF652
Smoking Status 1.29 4 2 4.4 0.22 7.8e-01 IQCH PHF5A RPS26 ZNF652
Allergy or Eczema 26.82 54 45 100.0 0.93 1.6e-32 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-3203P2.1 D2HGDH EFEMP2 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF3A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI RANBP6 RERE RIN3 RP11-396B14.2 RP11-400F19.8 RP11-574K11.5 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TDRKH TLR1 TMEM232 TNFSF4 TSLP UBAC2 ZNF652
Cardiovascular Disease 1.42 7 2 4.4 0.51 2.4e-01 EEFSEC KRT222 RERE SIK2 SLC22A5 ZNF652 ZNF76
Hypothyroidism (self reported) 3.15 12 5 11.1 -0.09 7.7e-01 AHI1 BACH2 CD247 FADS1 IL7R KIAA1109 PHF5A RERE RPS26 SPPL3 TLR1 UBAC2
Respiratory disease 29.78 66 59 131.1 1.00 2.9e-95 AC034220.3 ADAM19 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3203P2.1 D2HGDH DMWD EEFSEC EFEMP2 FADS1 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 MYBPH NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI PTP4A1 RANBP6 RERE RIN3 RP11-396B14.2 RP11-400F19.8 RP11-574K11.5 RP1-197B17.3 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TDRKH TLR1 TNFSF4 TSLP UBAC2 ZNF652 ZNF76
Type 2 Diabetes (T2D) (2018) 1.31 2 1 2.2 0.00 1.0e+00 JAZF1 KIF11
Lung FEV1/FVC ratio 4.78 23 15 33.3 -0.79 6.4e-08 ADAM19 BACH2 D2HGDH DMWD EEFSEC GLDC IL18R1 IL1RL1 IL7R KIAA1432 MED24 MYBPH ORMDL3 P4HA2-AS1 RP11-396B14.2 RP11-574K11.5 RPS26 SLC22A5 SLC9A2 SMAD3 STAT6 ZNF652 ZNF76
Lung FVC 1.88 14 10 22.2 -0.19 4.8e-01 AC034220.3 AHI1 CLEC16A IQCH KIF1B LINGO4 P4HA2-AS1 RIN3 RP11-574K11.5 RPS26 SLC22A5 SPPL3 STMN3 ZNF76
Neuroticism 0.97 4 0 0.0 -0.37 6.3e-01 AHI1 IQCH MED24 PHF5A
Chronotype (morning person) 1.11 2 0 0.0 0.00 1.0e+00 KIAA1109 MED24
Hair Pigment 0.15 6 4 8.9 0.34 5.0e-01 AHI1 JAZF1 KIAA1432 KIF1B KIF5A ZNF76
Hand grip strength (left) 1.87 5 4 8.9 -0.99 3.2e-05 AC034220.3 KIF1B P4HA2-AS1 SLC22A5 ZNF76
Number of treatments/medications taken 2.51 4 1 2.2 0.97 2.6e-02 CLEC16A P4HA2-AS1 SLC9A2 ZNF652
Relative age of first facial hair 0.96 1 0 0.0 0.00 1.0e+00 SPPL3
Systolic blood pressure, automated reading 1.07 2 0 0.0 0.00 1.0e+00 DMWD STMN3
Angina 1.26 2 1 2.2 0.00 1.0e+00 AFF3 ZNF652
Vitamin and mineral supplements 1.46 1 1 2.2 0.00 1.0e+00 STAT6
Medication: Metformin 1.36 1 0 0.0 0.00 1.0e+00 KIF11
Impedance of leg (right) 1.11 5 3 6.7 -0.23 7.1e-01 GPR182 RIN3 RP11-400F19.8 RPS26 ZNF652
Leg fat-free mass (left) 1.34 8 4 8.9 -0.88 7.6e-04 AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 TRIM38 ZNF76
Trunk fat percentage 1.01 5 3 6.7 0.73 1.6e-01 IQCH PHF5A RP11-400F19.8 SMAD3 TRIM38
Hand grip strength (right) 1.96 6 4 8.9 -0.97 9.1e-06 AC034220.3 KIF1B P4HA2-AS1 SLC22A5 STAT6 ZNF76
Current tobacco smoking 1.31 1 1 2.2 0.00 1.0e+00 PHF5A
Maternal smoking around birth 1.17 1 0 0.0 0.00 1.0e+00 PHF5A
Taking other prescription medications 4.24 7 2 4.4 0.92 3.7e-04 AHI1 D2HGDH GSDMA IL1RL1 IQCH ORMDL3 ZNF652
Age when periods started (menarche) 1.31 4 0 0.0 0.46 5.4e-01 EEFSEC IQCH RPS26 SPPL3
Heel bone mineral density (BMD) T-score, automated (left) 0.95 2 0 0.0 0.00 1.0e+00 FADS1 RERE
High blood pressure 1.68 10 4 8.9 0.56 6.1e-02 AC034220.3 EEFSEC IQCH P4HA2-AS1 POLI RERE RPS26 SIK2 SLC22A5 ZNF652
Hayfever, allergic rhinitis or eczema 23.91 49 41 91.1 0.94 3.4e-31 AHI1 BACH2 CD247 CLEC16A CTD-3203P2.1 D2HGDH EFEMP2 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R JAZF1 KIAA1109 KIAA1432 KIF3A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI RANBP6 RERE RIN3 RP11-396B14.2 RP11-400F19.8 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TLR1 TMEM232 TNFSF4 TSLP UBAC2 ZNF652
Multivitamins +/- minerals 1.30 1 0 0.0 0.00 1.0e+00 STAT6
Medication: Levothyroxine sodium 2.81 5 2 4.4 0.14 7.9e-01 AHI1 BACH2 FADS1 IL7R RPS26
Sitting height 1.23 7 6 13.3 -0.85 2.0e-03 AC034220.3 DMWD P4HA2-AS1 SLC22A5 STAT6 ZNF652 ZNF76
Chronic bronchitis/emphysema (father) 1.82 1 0 0.0 0.00 1.0e+00 IQCH
Body mass index (BMI) 0.96 4 2 4.4 -0.93 6.7e-02 RP11-400F19.8 RPS26 SMAD3 TRIM38
Impedance of leg (left) 1.11 7 3 6.7 -0.44 3.2e-01 GPR182 RIN3 RP11-400F19.8 RPS26 S100A11 SLC22A5 ZNF652
Leg predicted mass (left) 1.34 7 4 8.9 -0.98 4.6e-06 AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 ZNF76
Trunk fat mass 0.94 5 2 4.4 0.72 1.7e-01 IQCH PHF5A RP11-400F19.8 SMAD3 TRIM38
Waist circumference 1.04 4 3 6.7 0.38 6.2e-01 IQCH RP11-400F19.8 RPS26 SMAD3
Past tobacco smoking 1.19 2 1 2.2 0.00 1.0e+00 GLDC IQCH
Nervous feelings 0.81 1 0 0.0 0.00 1.0e+00 IQCH
Forced vital capacity (FVC) 1.41 7 3 6.7 -0.82 7.0e-03 AHI1 IQCH LINGO4 RP11-574K11.5 STMN3 TRIM38 ZNF76
Heel bone mineral density (BMD) T-score, automated (right) 1.05 2 2 4.4 0.00 1.0e+00 FADS1 RERE
Qualifications: None of the above 0.99 1 1 2.2 0.00 1.0e+00 RPS26
Heart attack 1.32 2 0 0.0 0.00 1.0e+00 KIF5A ZNF652
Allergy 30.79 64 53 117.8 -0.97 5.2e-53 AC034220.3 AFF3 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3203P2.1 D2HGDH EEFSEC EFEMP2 EPS15L1 FADS1 FPR3 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI RANBP6 RERE RIN3 RP11-396B14.2 RP11-400F19.8 RP11-574K11.5 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TDRKH TLR1 TMEM232 TNFSF4 TSLP UBAC2 ZNF652
Diabetes (self-reported) 1.35 3 1 2.2 0.00 1.0e+00 JAZF1 KIF11 RP11-400F19.8
Hayfever/allergic rhinitis (self-reported) 12.41 25 14 31.1 0.96 1.4e-20 BACH2 CD247 CLEC16A D2HGDH GLDC GPR182 IL18R1 IL1RL1 IL7R KIAA1109 KIAA1432 KRT222 LRRC32 ORMDL3 RANBP6 RP11-396B14.2 RPS26 SLC25A46 SLC9A2 SMAD3 STAT6 TLR1 TMEM232 TNFSF4 TSLP
Medication: Simvastatin 1.41 1 0 0.0 0.00 1.0e+00 DMWD
Fluid intelligence score 1.17 2 0 0.0 0.00 1.0e+00 AFF3 RPS26
Neuroticism score 1.00 1 0 0.0 0.00 1.0e+00 PHF5A
Weight 1.06 8 6 13.3 -0.45 1.9e-01 AC034220.3 IQCH P4HA2-AS1 RP11-400F19.8 RPS26 SLC22A5 SMAD3 TRIM38
Impedance of arm (right) 1.42 11 8 17.8 0.63 2.9e-02 EEFSEC GSDMA KIF1B LRRC32 MED24 NDFIP1 PHF5A RIN3 RPS26 SMAD3 ZNF652
Arm fat percentage (right) 1.05 5 3 6.7 0.67 2.1e-01 IQCH PHF5A RP11-400F19.8 SMAD3 ZNF76
Trunk fat-free mass 1.43 7 7 15.6 -0.98 5.8e-06 AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 ZNF76
Hip circumference 0.83 4 1 2.2 1.00 4.6e-03 IQCH SMAD3 STMN3 TRIM38
Father's age at death 1.66 1 0 0.0 0.00 1.0e+00 SLC22A5
Hair/balding pattern: Pattern 3 0.99 1 0 0.0 0.00 1.0e+00 AC034220.3
Number of live births 1.23 1 1 2.2 0.00 1.0e+00 FADS1
Forced expiratory volume in 1-second (FEV1) 2.19 11 6 13.3 -0.92 9.3e-06 ADAM19 AHI1 EEFSEC LINGO4 P4HA2-AS1 RP11-574K11.5 RPS26 SLC22A5 STMN3 TRIM38 ZNF76
Pulse rate 1.06 1 1 2.2 0.00 1.0e+00 FADS1
Qualifications: A levels/AS levels or equivalent 0.72 1 0 0.0 0.00 1.0e+00 RPS26
Mouth/teeth dental problems: Dentures 1.03 1 0 0.0 0.00 1.0e+00 TRIM38
Asthma 30.93 72 67 148.9 1.00 7.3e-152 AC034220.3 ADAM19 AFF3 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3203P2.1 D2HGDH DMWD EEFSEC EFEMP2 EPS15L1 FADS1 FPR3 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 MYBPH NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI PTP4A1 RANBP6 RERE RIN3 RP1-102E24.8 RP11-396B14.2 RP11-400F19.8 RP11-574K11.5 RP1-197B17.3 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TDRKH TLR1 TMEM232 TNFSF4 TRIM38 TSLP UBAC2 ZNF652 ZNF76
Medication: Ibuprofen (e.g. Nurofen) 1.36 1 1 2.2 0.00 1.0e+00 STAT6
Forced expiratory volume in 1-second (FEV1), Best measure 2.26 10 6 13.3 -0.91 4.7e-05 ADAM19 AHI1 EEFSEC LINGO4 P4HA2-AS1 RP11-574K11.5 RPS26 SLC22A5 TRIM38 ZNF76
Impedance of arm (left) 1.36 11 5 11.1 0.60 3.9e-02 CTD-2020K17.3 EEFSEC GSDMA KIF1B LRRC32 MED24 PHF5A RIN3 RPS26 SMAD3 ZNF652
Arm fat mass (right) 0.92 5 4 8.9 0.35 5.6e-01 IQCH RP11-400F19.8 RPS26 SMAD3 TRIM38
Trunk predicted mass 1.44 7 7 15.6 -0.98 5.6e-06 AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 ZNF76
Standing height 1.86 13 9 20.0 -0.76 7.2e-04 AC034220.3 AFF3 DMWD FADS1 IQCH P4HA2-AS1 PHF5A RERE SLC22A5 SPPL3 STAT6 ZNF652 ZNF76
Tense / 'highly strung' 1.18 2 0 0.0 0.00 1.0e+00 PHF5A RERE
Hair/balding pattern: Pattern 4 1.61 5 0 0.0 0.39 5.2e-01 CTD-2020K17.3 FADS1 IQCH KIF1B S100A11
Birth weight of first child 1.54 2 1 2.2 0.00 1.0e+00 RPS26 ZNF76
Peak expiratory flow (PEF) 1.47 3 2 4.4 0.00 1.0e+00 ADAM19 SLC22A5 ZNF76
Medication: Paracetamol 1.42 1 1 2.2 0.00 1.0e+00 STAT6
Headache pain in last month 1.95 3 1 2.2 0.00 1.0e+00 DMWD RPS26 STAT6
Medication for cholesterol, blood pressure or diabetes 1.39 2 1 2.2 0.00 1.0e+00 SIK2 ZNF652
Gout (self-reported) 1.57 1 1 2.2 0.00 1.0e+00 KIF5A
Hypothyroidism/myxoedema (self-reported) 2.93 6 3 6.7 -0.14 7.7e-01 AHI1 BACH2 CD247 IL7R KIAA1109 RPS26
Medication: Ventolin 100micrograms inhaler 13.20 29 8 17.8 0.99 9.8e-31 AFF3 AHI1 BACH2 CD247 CLEC16A CTD-2020K17.3 D2HGDH GLDC GPR182 GSDMA IL18R1 IL1RL1 ING5 IQCH KIAA1109 KIAA1432 LINGO4 LRRC32 NDFIP1 ORMDL3 RANBP6 RPS26 SLC22A5 SLC9A2 SMAD3 STAT6 TLR1 TSLP ZNF652
Birth weight 1.41 3 1 2.2 0.00 1.0e+00 KIF11 SIK2 ZNF76
Forced vital capacity (FVC), Best measure 1.38 8 2 4.4 -0.85 1.8e-03 AHI1 IQCH LINGO4 RP11-574K11.5 RPS26 STMN3 TRIM38 ZNF76
Body fat percentage 1.06 7 2 4.4 0.77 4.4e-02 IQCH PHF5A RERE RP11-400F19.8 SMAD3 TRIM38 ZNF76
Leg fat percentage (right) 1.27 7 1 2.2 0.63 1.3e-01 IQCH KRT222 RERE RP11-400F19.8 SMAD3 STMN3 TRIM38
Arm fat-free mass (right) 1.33 7 6 13.3 -0.98 3.2e-06 AC034220.3 MED24 P4HA2-AS1 RIN3 RPS26 SLC22A5 ZNF76
Comparative body size at age 10 1.17 3 1 2.2 0.00 1.0e+00 IQCH SMAD3 ZNF652
Worry too long after embarrassment 1.04 2 0 0.0 0.00 1.0e+00 AHI1 IQCH
Wheeze or whistling in the chest in last year 12.05 34 18 40.0 0.99 4.5e-37 ADAM19 AFF3 BACH2 CASC3 CD247 CLEC16A D2HGDH GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 ING5 JAZF1 KIAA1109 KIAA1432 LINGO4 LRRC32 MED24 ORMDL3 RERE RIN3 RP11-396B14.2 RP11-574K11.5 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 STMN3 TSLP UBAC2 ZNF652
Age at first live birth 1.16 1 0 0.0 0.00 1.0e+00 RPS26
Shortness of breath walking on level ground 1.39 1 0 0.0 0.00 1.0e+00 LRRC32
Qualifications: College or University degree 1.09 2 2 4.4 0.00 1.0e+00 AFF3 RPS26
Medication for pain relief, constipation, heartburn 1.53 1 1 2.2 0.00 1.0e+00 STAT6
Medication: Blood pressure 1.54 2 2 4.4 0.00 1.0e+00 SIK2 ZNF652
Angina (self-reported) 1.20 1 0 0.0 0.00 1.0e+00 ZNF652
Migraine (self-reported) 1.70 1 1 2.2 0.00 1.0e+00 STAT6
Medication: Ibuprofen 1.37 1 1 2.2 0.00 1.0e+00 STAT6
Medication: Allopurinol 1.40 1 1 2.2 0.00 1.0e+00 KIF5A
Medication: Seretide 50 evohaler 6.65 8 1 2.2 0.98 1.1e-10 BACH2 D2HGDH IL18R1 IL1RL1 P4HA2-AS1 SLC22A5 SMAD3 ZNF652
Mean time to correctly identify matches 0.92 1 0 0.0 0.00 1.0e+00 MED24
Whole body fat mass 0.93 7 3 6.7 0.53 2.2e-01 IQCH PHF5A RP11-400F19.8 RPS26 SMAD3 STMN3 TRIM38
Leg fat mass (right) 0.96 6 3 6.7 0.52 2.9e-01 IQCH RERE RP11-400F19.8 RPS26 SMAD3 TRIM38
Arm predicted mass (right) 1.34 7 6 13.3 -0.98 3.9e-06 AC034220.3 MED24 P4HA2-AS1 RIN3 RPS26 SLC22A5 ZNF76
Pulse rate, automated reading 1.21 3 1 2.2 0.00 1.0e+00 FADS1 RPS26 SIK2
Alcohol intake frequency. 1.12 2 0 0.0 0.00 1.0e+00 RPS26 STAT6
Comparative height size at age 10 1.61 8 6 13.3 -0.69 2.6e-02 AC034220.3 DMWD IQCH KIF11 P4HA2-AS1 SLC22A5 SMAD3 ZNF76
Overall health rating 0.91 1 1 2.2 0.00 1.0e+00 ZNF652
Chest pain or discomfort 2.13 1 0 0.0 0.00 1.0e+00 IL1RL1
Had major operations 1.24 1 0 0.0 0.00 1.0e+00 ZNF652
Medication: Aspirin 1.39 1 0 0.0 0.00 1.0e+00 SIK2
Supplements: Vitamin C 1.02 1 0 0.0 0.00 1.0e+00 ORMDL3
Knee pain experienced in last month 1.10 1 0 0.0 0.00 1.0e+00 RP11-396B14.2
Hypertension (Self-reported) 1.70 9 4 8.9 0.51 1.1e-01 AC034220.3 EEFSEC P4HA2-AS1 POLI RERE RPS26 SIK2 SLC22A5 ZNF652
Illnesses of father: Heart disease 1.72 2 0 0.0 0.00 1.0e+00 SIK2 SMAD3
Smoking status: Previous 1.19 1 0 0.0 0.00 1.0e+00 IQCH
Forced expiratory volume in 1-second (FEV1), predicted 1.73 4 4 8.9 -0.97 1.6e-03 AC034220.3 P4HA2-AS1 SLC22A5 ZNF76
Whole body fat-free mass 1.38 7 6 13.3 -0.97 8.1e-06 AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 ZNF76
Leg fat-free mass (right) 1.31 7 4 8.9 -0.98 3.7e-06 AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 ZNF76
Arm fat percentage (left) 1.01 6 3 6.7 0.69 1.3e-01 IQCH PHF5A RP11-400F19.8 SMAD3 TRIM38 ZNF76
Average weekly red wine intake 1.29 1 0 0.0 0.00 1.0e+00 RP11-400F19.8
Mood swings 0.79 1 0 0.0 0.00 1.0e+00 PHF5A
Long-standing illness, disability or infirmity 2.19 2 0 0.0 0.00 1.0e+00 IQCH ZNF652
Ever had bowel cancer screening 1.18 1 0 0.0 0.00 1.0e+00 SIK2
Diabetes diagnosed by doctor 1.51 2 1 2.2 0.00 1.0e+00 JAZF1 KIF11
Friendships satisfaction 1.09 1 0 0.0 0.00 1.0e+00 EFEMP2
Mouth/teeth dental problems: Mouth ulcers 1.66 1 0 0.0 0.00 1.0e+00 ORMDL3
Mineral and other dietary supplements 1.24 1 0 0.0 0.00 1.0e+00 STAT6
Medication: Aspirin 1.34 1 0 0.0 0.00 1.0e+00 SIK2
Illnesses of father: None of the above (group 1) 1.32 1 0 0.0 0.00 1.0e+00 SMAD3
Smoking status: Current 1.22 1 1 2.2 0.00 1.0e+00 PHF5A
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.15 6 2 4.4 -0.92 9.8e-03 ADAM19 ORMDL3 RPS26 STMN3 TRIM38 ZNF76
Whole body water mass 1.40 7 6 13.3 -0.97 8.7e-06 AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 ZNF76
Leg predicted mass (right) 1.32 7 4 8.9 -0.98 3.9e-06 AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 ZNF76
Arm fat mass (left) 0.92 5 3 6.7 0.37 5.4e-01 IQCH RP11-400F19.8 RPS26 SMAD3 TRIM38
Number of self-reported non-cancer illnesses 4.76 12 3 6.7 0.94 3.2e-07 D2HGDH EEFSEC IL1RL1 IQCH LINGO4 LRRC32 ORMDL3 P4HA2-AS1 PHF5A RP11-396B14.2 SLC22A5 ZNF652
Average weekly champagne plus white wine intake 1.18 1 0 0.0 0.00 1.0e+00 FADS1
Medication: Blood pressure 1.71 4 0 0.0 0.73 1.6e-01 AC034220.3 P4HA2-AS1 SIK2 SLC22A5
High cholesterol (Self-reported) 1.10 1 0 0.0 0.00 1.0e+00 FADS1
Medication: Bendroflumethiazide 1.63 3 0 0.0 0.99 1.4e-02 AC034220.3 P4HA2-AS1 SLC22A5
Medication: Paracetamol 1.16 1 1 2.2 0.00 1.0e+00 STAT6
Alcohol drinker status: Never 1.38 1 0 0.0 0.00 1.0e+00 SLC9A2
Basal metabolic rate 1.31 7 5 11.1 -0.98 1.8e-06 AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 ZNF76
Leg fat percentage (left) 1.30 8 1 2.2 0.64 8.5e-02 IQCH KRT222 RERE RP11-400F19.8 SMAD3 STMN3 TRIM38 ZNF76
Arm fat-free mass (left) 1.31 6 6 13.3 -0.99 5.8e-06 AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 ZNF76
Number of operations (self-reported) 1.43 1 0 0.0 0.00 1.0e+00 IQCH
Irritability 1.02 1 0 0.0 0.00 1.0e+00 FADS1
Fractured/broken bones in last 5 years 1.32 1 0 0.0 0.00 1.0e+00 IQCH
Age started oral contraceptive pill 1.09 1 0 0.0 0.00 1.0e+00 RPS26
Diastolic blood pressure, automated reading 1.39 5 1 2.2 0.98 3.6e-03 AC034220.3 P4HA2-AS1 RERE ZNF652 ZNF76
Myopia 1.41 1 0 0.0 0.00 1.0e+00 STAT6
Vascular/heart problems diagnosed by doctor 1.86 9 5 11.1 -0.64 3.5e-02 AC034220.3 EEFSEC IQCH P4HA2-AS1 RERE SIK2 SLC22A5 SMAD3 ZNF652
Cholesterol lowering medication 1.19 1 0 0.0 0.00 1.0e+00 DMWD
Pain experienced in last month 1.20 2 0 0.0 0.00 1.0e+00 RPS26 STAT6
Heart attack/myocardial infarction (self-reported) 1.38 1 0 0.0 0.00 1.0e+00 ZNF652
Impedance of whole body 1.22 9 5 11.1 0.33 3.8e-01 EEFSEC KIF1B LRRC32 MED24 PHF5A RIN3 RP11-400F19.8 RPS26 ZNF652
Leg fat mass (left) 0.97 7 3 6.7 0.52 2.4e-01 IQCH RERE RP11-400F19.8 RPS26 SMAD3 STMN3 TRIM38
Arm predicted mass (left) 1.36 6 6 13.3 -0.99 7.1e-06 AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 ZNF76

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 9 0.258 1.9
GTEx Adipose Visceral Omentum 8 0.393 2.0
GTEx Adrenal Gland 5 0.343 1.8
GTEx Artery Aorta 14 0.470 2.0
GTEx Artery Coronary 1 0.085 1.7
GTEx Artery Tibial 20 0.532 2.1
GTEx Brain Caudate basal ganglia 3 0.326 1.8
GTEx Brain Cerebellar Hemisphere 5 0.336 2.0
GTEx Brain Cerebellum 6 0.303 2.0
GTEx Brain Cortex 9 0.870 2.1
GTEx Brain Frontal Cortex BA9 5 0.541 2.0
GTEx Brain Hippocampus 2 0.382 1.7
GTEx Brain Hypothalamus 2 0.339 2.0
GTEx Brain Nucleus accumbens basal ganglia 7 0.809 2.1
GTEx Brain Putamen basal ganglia 3 0.481 2.1
GTEx Breast Mammary Tissue 10 0.507 2.1
GTEx Breast Mammary Tissue (Male) 6 0.503 2.2
GTEx Breast Mammary Tissue (Female) 6 0.365 1.9
GTEx Cells EBV-transformed lymphocytes 6 0.422 1.9
GTEx Cells Transformed fibroblasts 22 0.524 2.1
GTEx Colon Sigmoid 5 0.342 2.0
GTEx Colon Transverse 11 0.533 2.1
GTEx Esophagus Gastroesophageal Junction 5 0.346 1.9
GTEx Esophagus Mucosa 15 0.452 2.0
GTEx Esophagus Muscularis 13 0.402 2.0
GTEx Heart Atrial Appendage 7 0.443 2.1
GTEx Heart Left Ventricle 5 0.327 1.8
GTEx Liver 3 0.418 1.9
GTEx Lung 10 0.348 2.0
GTEx Muscle Skeletal 14 0.484 2.0
GTEx Nerve Tibial 15 0.347 2.0
GTEx Ovary 5 0.551 2.0
GTEx Pancreas 8 0.490 2.2
GTEx Pituitary 6 0.538 2.0
GTEx Prostate 4 0.479 1.9
GTEx Skin Not Sun Exposed Suprapubic 17 0.691 2.0
GTEx Skin Sun Exposed Lower leg 18 0.495 2.1
GTEx Small Intestine Terminal Ileum 1 0.217 1.7
GTEx Spleen 10 0.709 2.2
GTEx Stomach 5 0.344 1.9
GTEx Testis 16 0.507 2.0
GTEx Thyroid 19 0.475 2.1
GTEx Uterus 1 0.176 1.8
GTEx Vagina 0 0.000 1.7
GTEx Whole Blood 13 0.652 2.3
METSIM Adipose 19 0.412 2.0
NTR Blood 15 0.624 2.2
ROSMAP Brain Pre-frontal Cortex 20 0.455 2.0
YFS Blood 24 0.520 2.1
CommonMind Brain Pre-frontal Cortex 22 0.409 2.0
The Cancer Genome Atlas Bladder Urothelial Carcinoma 6 0.363 2.0
The Cancer Genome Atlas Breast Invasive Carcinoma 21 0.477 1.9
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 5 0.456 1.8
The Cancer Genome Atlas Colon Adenocarcinoma 11 0.533 2.0
The Cancer Genome Atlas Esophageal Carcinoma 3 0.438 1.9
The Cancer Genome Atlas Glioblastoma Multiforme 7 0.685 1.9
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 9 0.331 2.0
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 21 0.512 2.1
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 9 0.439 2.1
The Cancer Genome Atlas Brain Lower Grade Glioma 17 0.395 1.9
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 5 0.452 2.1
The Cancer Genome Atlas Lung Adenocarcinoma 14 0.477 2.1
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 17 0.678 2.2
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 6 0.377 1.8
The Cancer Genome Atlas Pancreatic Adenocarcinoma 9 0.542 2.2
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 3 0.226 1.9
The Cancer Genome Atlas Prostate Adenocarcinoma 15 0.324 1.9
The Cancer Genome Atlas Rectum Adenocarcinoma 6 0.868 2.1
The Cancer Genome Atlas Soft Tissue Sarcoma 2 0.187 1.8
The Cancer Genome Atlas Skin Cutaneous Melanoma 2 0.374 2.0
The Cancer Genome Atlas Stomach Adenocarcinoma 9 0.534 2.2
The Cancer Genome Atlas Testicular Germ Cell Tumors 8 0.625 2.1
The Cancer Genome Atlas Thyroid Carcinoma 28 0.543 2.1
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 2 0.394 1.8